Modella AI, a leader in artificial intelligence for life sciences, announces that it has been acquired by AstraZeneca, expanding the companies’ existing collaboration to advance the application of multi-modal AI foundation models and AI agents across AstraZeneca’s global oncology portfolio. The acquisition follows a multi-year agreement with AstraZeneca announced in July 2025 and will integrate Modella AI’s generative and agentic AI platform into AstraZeneca’s oncology research and development organization, supporting efforts to accelerate clinical development, enhance biomarker discovery, and enable the next wave of data-driven decision-making across the pipeline.
Read the full article: Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale //
Source: https://www.businesswire.com/news/home/20260113561240/en/Modella-AI-Announces-Acquisition-by-AstraZeneca-to-Advance-AI-Driven-Oncology-RD-at-Global-Scale